

## **Product datasheet for TL314059**

## **OriGene Technologies, Inc.** 9620 Medical Center Drive, Ste 200

Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

## CD93 Human shRNA Plasmid Kit (Locus ID 22918)

**Product data:** 

**Product Type:** shRNA Plasmids

Product Name: CD93 Human shRNA Plasmid Kit (Locus ID 22918)

**Locus ID:** 22918

**Synonyms:** C1qR(P); C1QR1; C1qRP; CDw93; dJ737E23.1; ECSM3; MXRA4

**Vector:** pGFP-C-shLenti (TR30023) **E. coli Selection:** Chloramphenicol (34 ug/ml)

**Mammalian Cell** 

Puromycin

Selection:

Format: Lentiviral plasmids

Components: CD93 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 22918).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 012072, NM 012072.1, NM 012072.2, NM 012072.3, BC028075, BC028075.1,

NM 012072.4

UniProt ID: 09NPY3

**Summary:** The protein encoded by this gene is a cell-surface glycoprotein and type I membrane protein

that was originally identified as a myeloid cell-specific marker. The encoded protein was once thought to be a receptor for C1q, but now is thought to instead be involved in intercellular adhesion and in the clearance of apoptotic cells. The intracellular cytoplasmic tail of this protein has been found to interact with moesin, a protein known to play a role in linking transmembrane proteins to the cytoskeleton and in the remodelling of the cytoskeleton.

[provided by RefSeg, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).